logo
New speed cameras coming to Knoxville school zones following City Council approval

New speed cameras coming to Knoxville school zones following City Council approval

Yahoo28-05-2025
KNOXVILLE, Tenn. (WATE) — The Knoxville City Council approved several agenda items Tuesday night by either a unanimous or 7-1 vote. Among the items passed were two items addressing speed and noise cameras in school zones.
The City of Knoxville aims to eliminating traffic fatalities on city roads by 2040, that plan is called 'Vision Zero.' Two items on Tuesday's agenda, one to acquire the products and services needs, the other to authorize the use of these automated enforcement systems were passed. They are two key pieces that city officials hope will help them reach their goal.
2025-26 Knoxville budget approved 7 to 1 by city council
'It's incredibly important. This was an item that was identified in our Vision Zero action plan. In the action plan, it identified 30 different action items,' Vision Zero Coordinator Cody Gentry said. 'Included in that 30 action items was to expand our automated enforcement program and that's exactly what we have done.'
Gentry said speeding is one of the main causes of fatal and injury crashes. The new speed cameras will hopefully help reduce speeding in school zones.
'In these school zones, that's where we have a lot of our vulnerable users, that's where we have kids walking to school, that's where we have a lot of pedestrian activity,' Gentry explained. 'We want, not only those students that are outside of the vehicles, but we want people driving through the school zones, we want the drivers and pedestrians, maybe parents, we want all of those users to be safe.'
Councilwoman Gwen Mckenzie echoed Gentry's thoughts.
'Safety in schools and for our children is paramount,' McKenzie said. 'We see speeding is really a bad habit that a lot of people have, so anything we can do to cut down on potential accidents happening and keeping our students safe, we're all about it.'
Second Harvest continues to feel federal cuts impact ahead of summer months
The implantation of the school zone speed and noise camera will happen in stages. The noise cameras will be placed first and the hope is to have some of the speed cameras up in a few areas by this Fall. This will all be prioritized based on traffic and speed studies in those areas.
One other item on the agenda that drew a long discussion was the Magnolia Avenue and Chilhowee Park redevelopment plan. The item passed 7-1, McKenzie said this redevelopment will bring life back to a once vibrant area.
'There's been a lot of disinvestment in that part of East Knoxville for quite some time now, over a decade,' McKenzie said. 'This particular resolution is critical to be able to make sure that happens and happens in a very uniform and structural way where the community has input as well.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ex-Biden ‘Politburo' aide Steve Ricchetti tells Oversight panel former prez was ‘fully capable,' no one usurped his powers
Ex-Biden ‘Politburo' aide Steve Ricchetti tells Oversight panel former prez was ‘fully capable,' no one usurped his powers

New York Post

time7 hours ago

  • New York Post

Ex-Biden ‘Politburo' aide Steve Ricchetti tells Oversight panel former prez was ‘fully capable,' no one usurped his powers

WASHINGTON — Steve Ricchetti, an ex-top aide to former President Joe Biden and member of his purported 'Politburo,' testified before the House Oversight Committee that his old boss was 'fully capable' of discharging his duties and that no one 'usurped' his executive powers. Ricchetti, 68, the former counselor to the president and staunch Biden fan, testified before the GOP-led panel for about eight and a half hours Wednesday as part of its probe into the 46th president's mental acuity and use of autopen. 'Let me be clear: At all times during his presidency, I believed that President Biden was fully capable of exercising his Presidential duties and responsibilities, and that he did so,' Ricchetti testified during his opening statement, per multiple reports. 'Neither I, nor anyone else, usurped President Biden's constitutional duties.' Advertisement 'I firmly believe that at all times during my four years in the White House, President Biden was fulfilling his constitutional duties. Did he stumble? Occasionally. Make mistakes? Get up on the wrong side of the bed? He did – we all did.' 3 Steve Ricchetti voluntarily cooperated with the GOP-led House Oversight Committee and sat for hours of testimony Wednesday. CQ-Roll Call, Inc via Getty Images Ricchetti is now the seventh Biden confidant to come before the panel and claims he did so voluntarily to combat the 'false narrative that President Biden was mentally unable to perform his Constitutional duties.' Advertisement The 68-year-old has long been in Democratic politics, having worked on Biden's campaign, served as his chief of staff during the latter half of his vice presidency, and as the White House deputy chief of staff for operations in the Clinton administration. For four years, Ricchetti played a critical role in shepherding Biden's legislative agenda. In the book 'Original Sin,' Ricchetti was described as one of five members in Biden's core inner circle, dubbed the 'Politburo' and described as the 'ultimate decision-makers' surrounding the 46th president. At one point, Ricchetti personally rang up a reporter to push back against claims from multiple sources about Biden's condition, according to the book. Advertisement 3 Former President Joe Biden has shrugged off concerns about his age and use of autopen. AP He also railed against actor George Clooney in the wake of the actor's stunning op-ed against Biden last July. 'Ricchetti read it and was furious. Internally, he threatened to shut Clooney down—some of his colleagues thought he sounded like a mob boss,' authors Alex Thompson and Jake Tapper recounted. Back in May, Oversight Committee Chairman James Comer (R-Ky.) began blasting out requests to former Biden aides to assist in a probe of the former president's use of autopen to sign key documents and whether they helped participate in a 'cover-up' of his mental cognition. Advertisement Ricchetti was summoned for testimony last month. Behind closed doors on Wednesday, Ricchetti took aim at the GOP-led Oversight panel, accusing it of participating in a 'concerted effort by the Administration and its Congressional allies to diminish the record of the former President.' 'I am not aware of any effort to use the autopen on important documents without the President's knowledge and consent,' Ricchetti added in his opening statement. 'I am not aware of any effort to keep important information from the President.' 'Senior White House staff kept the President fully informed so that he could provide direction and make all important decisions.' Biden, for his part, declared in a statement provided by his office that 'I made the decisions about the pardons, executive orders, legislation, and proclamations.' 'Any suggestion that I didn't is ridiculous and false.' 3 Steve Ricchetti was widely seen as being part of former President Joe Biden's innermost circle during his administration. AFP via Getty Images Asked about Ricchetti's testimony, Comer indicated that the Biden official was not very forthcoming. Advertisement 'He didn't tell us a whole lot of what you wouldn't expect,' the Kentucky Republican told Fox News 'Ingraham Angle' host Laura Ingraham. 'His testimony wasn't consistent with others who have actually testified,' Comer added, noting that about half the former White House officials the committee has brought in have asserted their Fifth Amendment rights. 'All their testimony is inconsistent,' Comer continued. 'So we're going to put the pieces together, and we're going to release all the transcripts, and we're going to issue a report, and hopefully we'll be able to determine whether or not Joe Biden had any idea who was using the autopen and what they were using it for.' The Trump administration has opened multiple probes into Biden's use of autopen that dovetail with the Oversight Committee's work. Advertisement Other aides to appear before the powerful investigative panel, including former White House Chief of Staff Ron Klain; Jill Biden's powerful former chief of staff Anthony Bernal; former presidential physician Dr. Kevin O'Connor; Ashley Williams, former special assistant to the president and deputy director of Oval Office Operations; and Neera Tanden, the former White House director of the Domestic Policy Council. Several of the Biden aides have pleaded the Fifth Amendment and declined to answer questions from the Oversight Committee. The powerful investigatory panel is slated to hear from former senior adviser Mike Donilon on Thursday.

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats
Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats

Business Wire

time12 hours ago

  • Business Wire

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats

SHAWNEE, Kan.--(BUSINESS WIRE)--PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats. Felycin®-CA1 is a specifically designed dosage formulation of sirolimus comprising an enteric coated delayed-release technology that results in a specific pharmacokinetic profile to ensure both the safety and effectiveness of Felycin®-CA1 for cats with HCM. The RAPACAT study was conducted to obtain conditional approval, while the HALT study is currently enrolling cats and being conducted to pursue the full new animal drug approval of Felycin®-CA1 for cats with HCM. 'The use of compounded rapamycin (sirolimus) or the human approved version of Rapamune® has not been approved by the FDA for the management of HCM in cats and has the potential to be very dangerous or even life-threatening if used in cats,' said Dr. Heather Davis DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services, Pegasus Laboratories, Inc. Feline HCM is extremely common, affecting 1 in 7 of all pet cats. In cats 9 years of age and older, the prevalence rises to approximately 1 in 3 and is a leading cause of mortality in adult cats. The disease is characterized by abnormal thickening and impaired function of the ventricular wall of the heart. While some cats remain asymptomatic, around half go on to develop congestive heart failure or other severe complications. Subclinical HCM refers to cases that have ventricular wall thickening but have not yet developed clinical signs. PBI-Gordon Companies, Inc. President & CEO Steve Clifford, added, 'We are very pleased to issue this update to provide both clarity and comfort for pet owners and veterinarians to ensure that cats with asymptomatic ventricular HCM are receiving the one and only FDA-conditionally approved prescription therapy for this condition.' Felycin®-CA1 is available now through licensed veterinarians nationwide and is set to fundamentally change the HCM treatment landscape – a market severely underserved. About PBI-Gordon Companies PBI-Gordon Companies has been in business in the Kansas City metro area since 1947 and is 100 percent employee-owned. It is the parent company to four subsidiaries which develop, manufacture, and market leading products for Turf and Ornamental (PBI-Gordon Corporation), Companion Animal Pharmaceuticals (Pegasus Laboratories & TriviumVet), and Companion Animal Nutritional Supplements and Grooming Supplies (PetAg). About Pegasus Laboratories Founded in 1986, Pegasus Laboratories is a pharmaceutical development and manufacturing organization focused on novel products to treat chronic conditions in cats, dogs, and horses. Pegasus provides full-service Contract Development and Manufacturing Organization (CDMO) focusing on the development and manufacturing with full turn-key technical services in an FDA-registered facility that is in compliance with current Good Manufacturing Practices (cGMPs). Pegasus also provides a full portfolio of pharmaceuticals, nutritional therapeutics and supplements, parasite control and surgical and wound care under the PRN® Pharmacal and Sē·Qual™ brands. About TriviumVet TriviumVet is an Ireland-based research and development company working with some of the leading veterinarians and therapeutic specialists around the world to address the gaps in disease management by developing innovative new therapeutic solutions for some of the most serious and underserved conditions. Focused on finding effective treatments for unmet needs in cardiology, renal health, pain management, gastroenterology, wellness testing, and age-related diseases.

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Con
Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Con

Business Wire

time12 hours ago

  • Business Wire

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Con

SHAWNEE, Kan.--(BUSINESS WIRE)--PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats. Felycin®-CA1 is a specifically designed dosage formulation of sirolimus comprising an enteric coated delayed-release technology that results in a specific pharmacokinetic profile to ensure both the safety and effectiveness of Felycin®-CA1 for cats with HCM. The RAPACAT study was conducted to obtain conditional approval, while the HALT study is currently enrolling cats and being conducted to pursue the full new animal drug approval of Felycin®-CA1 for cats with HCM. 'The use of compounded rapamycin (sirolimus) or the human approved version of Rapamune® has not been approved by the FDA for the management of HCM in cats and has the potential to be very dangerous or even life-threatening if used in cats,' said Dr. Heather Davis DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services, Pegasus Laboratories, Inc. Feline HCM is extremely common, affecting 1 in 7 of all pet cats. In cats 9 years of age and older, the prevalence rises to approximately 1 in 3 and is a leading cause of mortality in adult cats. The disease is characterized by abnormal thickening and impaired function of the ventricular wall of the heart. While some cats remain asymptomatic, around half go on to develop congestive heart failure or other severe complications. Subclinical HCM refers to cases that have ventricular wall thickening but have not yet developed clinical signs. PBI-Gordon Companies, Inc. President & CEO Steve Clifford, added, 'We are very pleased to issue this update to provide both clarity and comfort for pet owners and veterinarians to ensure that cats with asymptomatic ventricular HCM are receiving the one and only FDA-conditionally approved prescription therapy for this condition.' Felycin®-CA1 is available now through licensed veterinarians nationwide and is set to fundamentally change the HCM treatment landscape – a market severely underserved. About PBI-Gordon Companies PBI-Gordon Companies has been in business in the Kansas City metro area since 1947 and is 100 percent employee-owned. It is the parent company to four subsidiaries which develop, manufacture, and market leading products for Turf and Ornamental (PBI-Gordon Corporation), Companion Animal Pharmaceuticals (Pegasus Laboratories & TriviumVet), and Companion Animal Nutritional Supplements and Grooming Supplies (PetAg). About Pegasus Laboratories Founded in 1986, Pegasus Laboratories is a pharmaceutical development and manufacturing organization focused on novel products to treat chronic conditions in cats, dogs, and horses. Pegasus provides full-service Contract Development and Manufacturing Organization (CDMO) focusing on the development and manufacturing with full turn-key technical services in an FDA-registered facility that is in compliance with current Good Manufacturing Practices (cGMPs). Pegasus also provides a full portfolio of pharmaceuticals, nutritional therapeutics and supplements, parasite control and surgical and wound care under the PRN® Pharmacal and Sē·Qual™ brands. About TriviumVet TriviumVet is an Ireland-based research and development company working with some of the leading veterinarians and therapeutic specialists around the world to address the gaps in disease management by developing innovative new therapeutic solutions for some of the most serious and underserved conditions. Focused on finding effective treatments for unmet needs in cardiology, renal health, pain management, gastroenterology, wellness testing, and age-related diseases.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store